ICD-10 Code A30.5 | Lepromatous leprosy Symptoms, Diagnosis, Billing

Lepromatous leprosy is a chronic infectious disease caused by Mycobacterium leprae, characterized by extensive skin lesions, nerve damage, and systemic involvement. It is clinically significant due to its potential for severe disability and social stigma. Accurate coding with ICD-10 Code A30.5 ensures proper diagnosis, documentation, and billing, facilitating effective public health reporting and resource allocation.

What is ICD-10 Code A30.5 for Lepromatous leprosy?

ICD-10 Code A30.5 specifically denotes Lepromatous leprosy, a severe form of leprosy marked by numerous skin lesions and significant nerve damage. This code should be used in clinical documentation when diagnosing patients with this condition, ensuring accurate billing and tracking of healthcare services related to this infectious disease.

ICD-10 Code A30.5 – Clinical Definition and Explanation of Lepromatous leprosy

Lepromatous leprosy is caused by the bacterium Mycobacterium leprae, leading to a progressive disease that affects the skin, peripheral nerves, and mucous membranes. It requires prompt medical attention to prevent complications and disability. The condition is characterized by a high bacterial load and a weak immune response.

Key Clinical Features:

• Presence of multiple skin lesions, often with a thickened appearance.
• Nerve damage leading to loss of sensation and muscle weakness.
• Facial deformities due to skin and nerve involvement.
• Systemic symptoms such as fever and malaise in advanced cases.

ICD-10 Code A30.5 for Lepromatous leprosy – SOAP Notes & Clinical Use

In SOAP notes, ICD-10 Code A30.5 is utilized to document the diagnosis of Lepromatous leprosy, aiding in the assessment of symptoms and treatment plans. This code is relevant in both acute and chronic care settings, ensuring comprehensive patient management.

What Does ICD-10 Code A30.5 for Lepromatous leprosy Mean in SOAP Notes?

ICD-10 Code A30.5 connects subjective patient reports and objective clinical findings to a formal diagnosis of Lepromatous leprosy. This code is essential for ensuring continuity of care, supporting accurate billing, and meeting EHR documentation standards.

Treatment Options for ICD-10 Code A30.5 – Lepromatous leprosy

Lepromatous leprosy requires urgent medical intervention, often necessitating hospitalization for severe cases. Treatment typically involves multidrug therapy to eradicate the infection.

Antibiotic Therapy:

• Rifampicin: 600 mg once monthly.
• Dapsone: 100 mg daily.
• Clofazimine: 300 mg once monthly and 50 mg daily.

Supportive Care:

• Regular monitoring of nerve function and skin lesions.
• Physical therapy to maintain mobility and function.
• Psychosocial support to address stigma and mental health.

Infection Control:

• Isolation of patients during the initial phase of treatment.
• Education on hygiene practices to prevent transmission.
• Vaccination and prophylaxis for close contacts in outbreak situations.

How to Document Symptoms of Lepromatous leprosy (ICD-10 A30.5) in SOAP Notes

Subjective:

• Patient reports numbness and tingling in extremities.
• History of skin lesions that have progressively worsened.
• Complaints of fatigue and malaise.
• Social stigma and anxiety regarding diagnosis.

Objective:

• Multiple hypopigmented skin lesions observed on examination.
• Decreased sensation in affected areas on monofilament testing.
• Thickened peripheral nerves palpated.
• Laboratory confirmation of Mycobacterium leprae via skin biopsy.

Secure, compliant, and built for trust

HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.

Learn more

SOAP Note Guidelines for Diagnosing Lepromatous leprosy (ICD-10 Code A30.5)

Assessment:

• Diagnosis: Lepromatous leprosy, severe form.
• ICD-10 Code: A30.5.
• Contributing factors: Poor immune response and prolonged exposure.
• Triggers: Close contact with untreated individuals.

Plan:

• Initiate multidrug therapy with Rifampicin, Dapsone, and Clofazimine.
• Educate patient on disease management and treatment adherence.
• Schedule follow-up appointments for monitoring treatment response.
• Refer to mental health services for psychosocial support.

Treatment & Plan Section for ICD-10 Code A30.5 – Lepromatous leprosy

• First-line pharmacologic treatments include Rifampicin, Dapsone, and Clofazimine.
• Non-pharmacologic strategies involve patient education and psychosocial support.
• Monitoring practices include regular assessments of skin lesions and nerve function.
• Follow-up recommendations should be made every 1-3 months during treatment.

Using ICD-10 Code A30.5 for Lepromatous leprosy in Billing & SOAP Note Compliance

• Select accurate subcodes based on clinical severity or complications.
• Document symptoms clearly under Subjective (S) and Objective (O) in SOAP notes.
• Ensure treatment plans align with clinical guidelines to support justified billing.
• Only list CPT codes that are commonly billed with ICD-10 Code A30.5 based on standard medical coding practices.

Related ICD-10 Codes Often Used with Lepromatous leprosy

• A30.0 – Tuberculoid leprosy
• A30.1 – Borderline leprosy
• A30.2 – Indeterminate leprosy
• A30.3 – Leprosy, unspecified
• A30.4 – Lepromatous leprosy with reaction

ICD-10 Code A30.5 in Medical Billing and Insurance for Lepromatous leprosy

ICD-10 Code A30.5 is crucial for billing in hospital, ER, or infectious disease care settings, ensuring accurate reimbursement for services rendered.

Billing Notes:

• Document all relevant patient history and clinical findings to support the diagnosis.
• Use the code in conjunction with appropriate CPT codes for comprehensive billing.
• Ensure that the documentation reflects the severity and complexity of the condition.
• Review payer-specific guidelines for coding and billing requirements.

Common CPT Pairings: